Search Results - "HEWISON, C"

Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment" by Cox, V., Guglielmetti, L., Hewison, C., Reuter, A., Furin, J.

Get full text

Mobile community-based active case-finding for tuberculosis among older populations in rural Cambodia by Camelique, O., Scholtissen, S., Dousset, J.-P., Bonnet, M., Bastard, M., Hewison, C.

“…OBJECTIVE: To systematically screen older rural populations in Cambodia for tuberculosis (TB) and develop an effective active case-finding (ACF) model for this…”
Get full text

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia by Hewison, C., Bastard, M., Khachatryan, N., Kotrikadze, T., Hayrapetyan, A., Avaliani, Z., Kiria, N., Yegiazaryan, L., Chumburidze, N., Kirakosyan, O., Atshemyan, H., Qayyum, S., Lachenal, N., Varaine, F., Huerga, H.

“…BACKGROUND AND SETTING: Bedaquiline (BDQ) was initially only available through compassionate use programmes.OBJECTIVE: To assess the effectiveness and safety…”
Get full text

Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries by Guglielmetti, L., Hewison, C., Avaliani, Z., Hughes, J., Kiria, N., Lomtadze, N., Ndjeka, N., Setkina, S., Shabangu, A., Sikhondze, W., Skrahina, A., Veziris, N., Furin, J.

“…BACKGROUND: For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and…”
Get full text

Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study by Bonnet, M., Bastard, M., du Cros, P., Khamraev, A., Kimenye, K., Khurkhumal, S., Hayrapetyan, A., Themba, D., Telnov, A., Sanchez-Padilla, E., Hewison, C., Varaine, F.

“…BACKGROUND: The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four…”
Get full text

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications by Rich, M. L., Khan, U., Zeng, C., LaHood, A., Franke, M. F., Atwood, S., Bastard, M., Burhan, E., Danielyan, N., Dzhazibekova, P. M., Gadissa, D., Ghafoor, A., Hewison, C., Islam, M. S., Kazmi, E., Khan, P. Y., Lecca, L., Maama, L. B., Melikyan, N., Naing, Y. Y., Philippe, K., Saki, N. A., Seung, K. J., Skrahina, A., Tefera, G. B., Varaine, F., Vilbrun, S. C., Võ, L., Mitnick, C. D., Huerga, H., on behalf of the endTB Observational Study Team

“…BACKGROUND: Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB)…”
Get full text

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB by Zeng, C., Mitnick, C. D., Hewison, C., Bastard, M., Khan, P., Seung, K. J., Rich, M. L., Atwood, S., Melikyan, N., Morchiladze, N., Khachatryan, N., Khmyz, M., Restrepo, C. G., Salahuddin, N., Kazmi, E., Dahri, A. A., Ahmed, S., Varaine, F., Vilbrun, S. C., Oyewusi, L., Gelin, A., Tintaya, K., Yeraliyeva, L. T., Hamid, S., Khan, U., Huerga, H., Franke, M. F.

“…BACKGROUND: The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these…”
Get full text

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB by Cox, V., McKenna, L., Acquah, R., Reuter, A., Wasserman, S., Vambe, D., Ustero, P., Udwadia, Z., Triviño-Duran, L., Tommasi, M., Skrahina, A., Seddon, J. A., Rodolfo, R., Rich, M., Padanilam, X., Oyewusi, L., Ohler, L., Lungu, P., Loveday, M., Khan, U., Khan, P., Hughes, J., Hewison, C., Guglielmetti, L., Furin, J.

“…Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB)…”
Get full text

What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis? by Bastard, M., Sanchez-Padilla, E., Hayrapetyan, A., Kimenye, K., Khurkhumal, S., Dlamini, T., Fadul Perez, S., Telnov, A., Hewison, C., Varaine, F., Bonnet, M.

“…INTRODUCTION: Identification of good prognostic marker for tuberculosis (TB) treatment response is a necessary step on the path towards a surrogate marker to…”
Get full text

Setting up pharmacovigilance based on available endTB Project data for bedaquiline by Lachenal, N., Hewison, C., Mitnick, C., Lomtadze, N., Coutisson, S., Osso, E., Ahmed, S., Leblanc, G., Islam, S., Atshemyan, H., Nair, P., Kholikulov, B., Aiylchiev, S., Zarli, K., Adnan, S., Krisnanda, A., Padayachee, S., Stambekova, A., Sahabutdinova, Y., de Guadalupe, S., Moreno, Perea, Kumsa, A., Reshid, A., Makaka, J., Abebe, S., Melikyan, N., Seung, K. J., Khan, U., Khan, P., Huerga, H., Rich, M., Varaine, F.

“…SETTING: Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched…”
Get full text

Introducing new and repurposed TB drugs: the endTB experience by Seung, K. J., Khan, U., Varaine, F., Ahmed, S., Bastard, M., Cloez, S., Damtew, D., Franke, M. F., Herboczek, K., Huerga, H., Islam, S., Karakozian, H., Khachatryan, N., Kliesckova, J., Khan, A. J., Khan, M., Khan, P., Kotrikadze, T., Lachenal, N., Lecca, L., Lenggogeni, P., Maretbayeva, S., Melikyan, N., Mesic, A., Mitnick, C. D., Mofolo, M., Perrin, C., Richard, M., Tassew, Y. M., Telnov, A., Vilbrun, S. C., Wanjala, S., Rich, M. L., Hewison, C.

“…In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs…”
Get full text

Analysis of 3D strain in the human medial meniscus by Kolaczek, S., Hewison, C., Caterine, S., Ragbar, M.X., Getgood, A., Gordon, K.D.

“…This study presents a method to evaluate three-dimensional strain in meniscal tissue using medical imaging. Strain is calculated by tracking small teflon…”
Get full text

Tuberculosis treatment in a refugee and migrant population: 20 years of experience on the Thai-Burmese border by MINETTI, A, CAMELIQUE, O, HSA THAW, K, THI, S, SWADDIWUDHIPONG, W, HEWISON, C, PINOGES, L, BONNET, M, GUERIN, P. J

“…SETTING: Although tuberculosis (TB) is a curable disease, it remains a major global health problem and an important cause of morbidity and mortality among…”
Get full text

The 'frozen state' of drug-resistant tuberculosis: notes from the field in Abkhazia by Majumdar, S., O'Brien, D., Hurtado, N., Hewison, C., du Cros, P.

Get full text

Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden by Bonnet, Maryline M B, Pinoges, Loretxu L P, Varaine, Francis F V, Oberhauser, Barbara B O, O'Brien, Daniel D O, Kebede, Yared Y K, Hewison, Cathy C H, Zachariah, Rony R Z, Ferradini, Laurent L F

“…HAART reduces tuberculosis (TB) incidence in people living with HIV/AIDS but those starting HAART may develop active TB or subclinical TB may become apparent…”
Get full text

Frozen tail or limber tail in working dogs by Hewison, C

Get full text

Integrating hepatitis C treatment into multidrug-resistant TB care by Kirakosyan, O., Melikyan, N., Falcao, J., Khachatryan, N., Atshemyan, H., Oganezova, I., Aznauryan, A., Yeghiazaryan, L., Sargsyants, N., Hayrapetyan, A., Balkan, S., Hewison, C., Huerga, H.

“…BACKGROUND: Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or…”
Get full text

In reply by Hewison, C, Bastard, M, Varaine, F, Huerga, H

Get full text

In reply by Hewison, C., Bastard, M., Varaine, F., Huerga, H.

Get full text

In reply by Hewison, C., Bastard, M., Varaine, F., Huerga, H.

Get full text